🔗 Share this article

As the US continues making sweeping revisions to its vaccine schedules, an unexpected name appears somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccines throughout the global health crisis and has concentrated on alleged fatalities after Covid immunization in her short time at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Health officials were set to unveil major revisions to the childhood vaccine schedule recently, aligning the US with the Danish national calendar, according to reports – a significant shift that would place the US out of alignment with many the global community with no evidence for improved outcomes. The planned update has been postponed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the center this year.

Consolidating Power at the Agency

This interim role might represent a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific pediatric immunization guidelines in the US so as to align more similar to Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the size of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Qualifications

The appointee has little discernible background in medication creation, oversight or management, which has been customary for past leaders of the biologics center. She has served at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for running the CDER, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a major agency. She has no expertise in industry regulation.”

Past directors of CBER would “understand regulatory frameworks and the science of pharmaceutical innovation”, noted Janet Woodcock. “Clearly, she lacks the kind of background that prior appointees who ran CBER have had.”

This division has an vast portfolio at the agency, she emphasized.

“Everybody just zeroes in on the new drug program, but the generic program approves thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and so forth, and each of these must be managed,” Dr. Woodcock said. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major leadership aspect to the position, which oversees over 5,000 employees. “It is a massive leadership role, if you execute it properly,” the former official added.

Response and Controversial Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on vaccines, a spokesperson responded that the “concerns are based on incorrect premises”.

“Her resume aligns with the duties of her job,” the official explained, noting the time Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Høeg inherits the agency head's new expedited review system, a disputed one-day drug-approval program that apparently concerned her former heads. “By what process are these drugs being selected for this voucher program? Who makes the decisions?” Howard said. “There is a lot of secrecy happening at the FDA right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards less stringent oversight of all drugs, with the exception of immunizations.”

Documented History on Vaccines

With vaccines, Høeg has a clearer, if concerning, history, Howard said. She authored a analysis using non-validated volunteer-provided data to determine the frequency of heart inflammation following Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the current federal leadership encompassed changing regulations for new vaccines and halting “non-essential” immunizations, she remarked following the vote on a online show. At the agency, Dr. Høeg has according to sources floated the idea of preventing adolescent males from obtaining Covid vaccines.

“She is an complete true believer who begins with her beliefs and tailors the evidence to accommodate the science in a extremely misleading, dishonest manner,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|